Soligenix Advances Novel Therapeutic for Hard-to-Diagnose Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) represents one of the most diagnostically challenging cancers in its early stages, with symptoms frequently mimicking common dermatologic conditions like eczema or psoriasis. This resemblance leads to frequent misdiagnosis and delayed treatment, allowing the disease to progress silently for years while increasing patient suffering and complicating care. Within this challenging diagnostic and treatment landscape, Soligenix Inc. (NASDAQ: SNGX) is advancing a novel therapeutic approach for CTCL through its development of HyBryte™.

CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin. The delayed diagnosis has meaningful clinical consequences, as patients often endure years of recurring rashes, itching, and skin lesions before receiving a correct diagnosis because early CTCL lesions can be indistinguishable from benign skin conditions. As a late-stage biopharmaceutical company, Soligenix is developing therapies aimed at addressing critical gaps in rare disease treatment, including CTCL. The company's focus on this difficult-to-diagnose condition highlights the urgent need for improved therapeutic options in the oncology space.

The development of HyBryte™ represents a significant step forward in addressing the treatment challenges associated with CTCL. By targeting this specific form of lymphoma, Soligenix is working to provide clinicians with additional tools to manage a disease that has historically proven difficult to treat effectively in its early stages. The company's progress in this area is particularly important given the diagnostic delays that characterize CTCL, which can span multiple years before patients receive appropriate care.

For investors seeking additional information, the latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. This development occurs within the broader context of specialized communications platforms like BioMedWire, which focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions, including access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. More information about this platform is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.